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Background: The capacity of cancer cells to undergo epithelial mesenchymal trans-
differentiation has been implicated as a factor driving metastasis, through the acquisition
of enhanced migratory/invasive cell programs and the engagement of anti-apoptotic mech-
anisms promoting drug and radiation resistance. Our aim was to define molecular signaling
changes associated with mesenchymal trans-differentiation in two KRas mutant NSCLC
models. We focused on central transcription and epigenetic regulators predicted to be
important for mesenchymal cell survival.
Experimental design: We have modeled trans-differentiation and cancer stemness in
inducible isogenic mutant-KRas H358 and A549 non-small cell lung cell backgrounds. As
expected, our models show mesenchymal-like tumor cells acquire novel mechanisms of
cellular signaling not apparent in their epithelial counterparts. We employed large-scale
quantitative phosphoproteomic, proteomic, protein–protein interaction, RNA-Seq, and net-
work function prediction approaches to dissect the molecular events associated with the
establishment and maintenance of the mesenchymal state.
Results: Gene-set enrichment and pathway prediction indicated BMI1, KDM5B, RUNX2,
MYC/MAX, NFκB, LEF1, and HIF1 target networks were significantly enriched in the trans-
differentiation of H358 and A549 NSCLC models. Physical overlaps between multiple
networks implicate NR4A1 as an overlapping control between TCF and NFκB pathways.
Enrichment correlations also indicated marked decrease in cell cycling, which occurred early
in the EMT process. RNA abundance time course studies also indicated early expression
of epigenetic and chromatin regulators within 8–24 h, including CITED4, RUNX3, CMBX1,
and SIRT4.
Conclusion: Multiple transcription and epigenetic pathways where altered between
epithelial and mesenchymal tumor cell states, notably the polycomb repressive complex-1,
HP1γ, and BAF/Swi-Snf. Network analysis suggests redundancy in the activation and inhi-
bition of pathway regulators, notably factors controlling epithelial cell state. Through large-
scale transcriptional and epigenetic cell reprograming, mesenchymal trans-differentiation
can promote diversification of signaling networks potentially important in resistance to
cancer therapies.
Keywords: tumor heterogeneity, epigenetic, transcription, systems biology, EMT
INTRODUCTION
Cellular plasticity in epithelial cancers is associated with a pro-
gression to a metastatic state (1, 2) and resistance to anti-cancer
therapies (3, 4). Over 90% of cancer patient deaths are attribut-
able to complications arising from metastatic dissemination of
cancer cells to distant organ sites. Tumor plasticity associated
with epithelial mesenchymal transition (EMT) (5, 6) contributes
to metastasis, drug resistance and is correlated with poor prog-
nosis (7, 8). The epigenetic reprograming associated with EMT
promotes the disassembly of epithelial cell-junctions, a loss of
epithelial polarity (4, 9), and the formation of molecular assem-
blies allowing cell migration and invasion (10). In multiple model
systems, EMT-derived mesenchymal cells can show the properties
of cancer stem cells including tumor initiation at low cell inocu-
lation in vivo, sphere formation in vitro, and CD44high, CD24low,
and ALDH1active pluripotent stem cell markers (11, 12). Despite
advances in the treatment of non-small cell lung cancers (NSCLC),
for example, the development of EGFR tyrosine kinase inhibitors
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(EGFR TKIs) for patients with activating EGFR mutations, sur-
vival rates for patients with mutant-KRas lung cancer are poor.
Mutant-KRas is observed in ~20% of NSCLC cases and is gen-
erally independent of EGFR mutations (13). In a recent clinical
study, the median survival time of patients treated with standard
of care was 7.7 months in NSCLC patients with mutant-KRas, in
marked contrast to 38 months in patients with mutant EGFR (14).
Several studies suggest tumor cells harboring mutant-KRas may be
primed to undergo epithelial mesenchymal trans-differentiation,
for example (15, 16). These mesenchymal-like carcinoma cells
have been shown to be resistant to many conventional lung cancer
therapies, including taxanes, pemetrexed, gemcitabine, and EGFR
TKIs (8, 12, 17). Chemotherapy has been shown to promote selec-
tion for EMT-derived cells in a number of solid tumor types (7,
17, 18) and conversely markers of EMT appears to contribute to
chemotherapy resistance (19) and predict response to EGFR and
PI3K inhibitors (20). Similar data show EMT-derived cells can
serve as reservoirs for cancer recurrence in relevant genetically
engineered models (21, 22). Therapies are needed that specifi-
cally target drug resistant mesenchymal-like tumor cells. However,
survival signaling networks in EMT–derived cells appear heteroge-
neous and critical dependencies common to mesenchymal tumor
cells remain ill defined. Current inhibitors of mesenchymal stem-
like tumor cells have been largely restricted to specific tumor
and driver types, for example, JAK or PDGFR inhibitors. Since
mesenchymal trans-differentiation involves an epigenetic repro-
graming, the pharmacological use of epigenetic modulators would
appear attractive. However, initial therapeutic successes with sin-
gle agent DNA methyltransferase inhibitors, HDAC inhibitors, and
EZH2 inhibitors have been more pronounced in the hematologic
malignancies, as opposed to epithelial-derived carcinomas, which
can undergo EMT.
In order to understand and identify transcriptional and epi-
genetic networks in a mutant-KRas mesenchymal cell context,
we have modeled metastable reversible EMT in two NSCLC cell
backgrounds. “Metastable” refers to a reversible EMT, achieved
for example by withdrawal of inducer (23), where in interme-
diate stages cells can express both epithelial and mesenchymal
markers (24). Here, we compared CD44low A549 cells with iso-
genic CD44high A549/transforming growth factor beta (TGFβ)
cells and CDH1/E-cadherinhigh H358 cells with isogenic CDH1low
H358/dox-TGFβ cells. As expected both models reversibly undergo
EMT and are less responsive to paclitaxel, gemcitabine, and
erlotinib in the mesenchymal state (data not shown). These mod-
els confirm the clinical observations and show that tumor cells that
have undergone EMT show increased resistance to standard of care
cancer treatments. Importantly, upon undergoing EMT tumor
cells acquire novel mechanisms of cellular signaling and resistance
to apoptosis not apparent in their epithelial counterparts.
We sought to define at signaling network changes distinguish-
ing epithelial and mesenchymal tumor states, with an aim of
identifying key nodes important in mesenchymal cell survival.
Pharmacological blockade of mesenchymal survival pathways may
overcome a limitation of current therapies, which preferentially
impact tumor cells with an epithelial phenotype (17). We used a
combination of RNA-Seq, phosphoproteomic, and bioinformat-
ics approaches to identify transcriptional and epigenetic networks
modulated as a consequence of epithelial mesenchymal transi-
tion (EMT). We employed TGFβ to induce EMT in the A549 and
H358 NSCLC models, where cells were preselected for a starting
epithelial state. TGFβ is a physiologically relevant inducer of EMT
(25) associated with a macrophage/monocyte rich inflammatory
microenvironment (26). Detailed RNA, protein, and phosphopep-
tide abundance datasets were obtained. Using pathway prediction
and gene-set enrichment approaches, and protein–protein inter-
action data we observed altered regulation of transcriptional,
epigenetic, and chromatin modulators and explored intersections
between key pathways.
MATERIALS AND METHODS
CELL CULTURE CONDITIONS
Parental H358 and A549 cells were obtained from the ATCC and
maintained in RPMI 1640 containing 10% FCS. Both H358 and
A549 are related adenocarcinoma NSCLC lines,where both express
an activated KRas oncogene, with mutations at G12C and G12S,
respectively. H358 cells harbor pathogenic mutations in CTNNB1,
KRAS, LIMK1, MAX, MED12, MSH3, PML, RNF212, RUNX2,
SATB2, SF3B1, SGK3, TP63, and USP2. A549 adenocarcinoma
NSCLC cells harbor pathogenic mutations in DCLK3, FRMD6,
KEAP1, KRAS, PTPN21, and TCEA2 (27). Both cell lines undergo
EMT in response to TGFβ. All cells were kept at 37°C with 5%
CO2. The TGFβ inducible variant of H358 and its dox-vector
control line were both engineered from a single H358 cell clone
with marker expression CDH1high and epithelial cell-junctions.
Multiple H358-dox-TGFβ cell lines were isolated (23, 24) using
the doxycycline inducible CMV promoter (pTRE2puro; invit-
rogen.com) using the two vector TET repressor/TET activator
system (ptTS, prTA; blaR) based on Ref. (28). H358-dox-TGFβ
clones were maintained in RPMI 1640, 10% tetracycline-free FCS
(clontech.com), L-glutamine (1 mM), sodium pyruvate (1 mM),
D-glucose (4.5 g/l), 10 mM HEPES, blasticidin (10µg/ml), and
doxycycline (0.5µg/ml). Doxycycline (0.5µg/ml) induction of
transgene expression was verified by immunoblot and was shown
to correctly modulate EMT marker expression (Figure S1 in Sup-
plementary Material). Inducible RNA expression (log2 FC= 4.6)
is shown in Table S1 in Supplementary Material. Parental A549
cells were anti-CD44 antibody selected using magnetic beads into
a CD44low starting epithelial population, which was subsequently
induced with TGFβ (10 ng/ml) to yield a uniformly mesenchymal
cell population after 7 days.
RNA-Seq
Duplicate cell samples (~3× 106 cells) were lyzed in 600µl Qiagen
RLT buffer, 1% β-mercaptoethanol, followed by column isolation
(qiagen.com). RNA isolation, library construction, and RNA-Seq
essentially followed Illumina protocols (illumina.com). cDNA was
prepared from total RNA with globin RNA reduction, followed
by library generation (Illumina True Seq). cDNA libraries were
immobilized (Illumina, Standard Cluster Generation Kit) and
sequenced on an Illumina HySeq instrument. Read depths for
H358 and A549 were 30 million and 25 million, respectively. RNA-
Seq was performed on Illumina HySeq instrument1 . FASTQ file
1http://www.expressionanalysis.com
Frontiers in Oncology | Molecular and Cellular Oncology December 2014 | Volume 4 | Article 344 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Haley et al. Epigenetic and transcription networks in NSCLC EMT
reads passing Illumina purity filter (PF reads) were aligned and
quantitation performed by RSEM (29), generating files where nor-
malized counts for each detected gene and isoform (UCSC Known
Gene). Aligned RNAs (27976 genes; 48241 isoforms) passing QC
thresholds were used to calculate mesenchymal–epithelial tran-
script abundance ratios followed by log2 linear scaling. Additional
analysis was performed using Cufflinks (30) on BAM files aligned
to hg19. For RNA-Seq data were selected where log2 fold change
(FC) was ≥1.0 and where rsem reads were >5 in any sample.
In difference analysis where either numerators or denominators
were equal to zero, values were generated (specified as >5 or <5)
in gene lists if differences >10 rsem reads were observed in both
H358 and A549 models with concordant log2 signs. Concordance
required >2 FC in three out of four samples (Mes-1 and Mes-2
over Epi-ave) for both A549 and H358 cell models.
PREPARATION OF CELL EXTRACTS AND PHOSPHORYLATION DIRECTED
AFFINITY CHROMATOGRAPHY
Essentially, site-specific serine and threonine phosphorylation
changes were measured by SILAC labeling of proteins, trypsin
digestion, ion-exchange fractionation, and TiO2 affinity selec-
tion in the presence of 1 M lactic acid to minimize acidic pep-
tide binding followed by nano LC-MS/MS. Site-specific tyro-
sine phosphorylation was measured by SILAC labeling, pep-
tide anti-phosphotyrosine selection, and nano LC-MS/MS. Total
protein changes were assessed by SILAC labeling, ion-exchange
fractionation, and LC-MS/MS.
Approximately 5× 108 H358 or A549 mesenchymal and epithe-
lial cells were cultured in RPMI 1640 media containing heavy
(13C6) arginine and lysine or light (12C) arginine and lysine,
respectively [SILAC; (31)]. Cells from five biological replicates
were extracted in 8 M urea, 50 mM HEPES, 2.5 mM sodium
pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium ortho-
vanadate, and phosphatase inhibitor cocktails 1 and 2 (1:100
dilution; sigmaaldrich.com). Heavy and light extracts were mixed,
sonicated for 2× 30 s and centrifuged at 10,000× g. The com-
bined supernatant was subjected to reduction (5 mM tributyl
phosphine), alkylation (15 mM iodoacetamide), proteolysis with
trypsin, desalting on C18 resin (Sep-Pak C18; waters.com) and
lyophilization. Peptides were immunoprecipitated with anti-
phosphotyrosine affinity resin essentially as described (32),
with C18 cartridge (Opti-Lynx 40µg C18AQ; optimizetech.com)
desalting with a 10 min gradient elution with inline UV absorbance
detection at 220 nm using a 250 nl flow cell. Peptides were
lyophilized, resuspended in 0.1% formic acid, and analyzed by
LC-MS/MS.
Anti-phosphotyrosine flow through peptides were separated
by SCX ion-exchange chromatography (SampliQ resin 150 mg;
agilent.com) in 10 mM KH2PO4 pH 3.0, 25% acetonitrile step
eluted with increasing KCl (20, 40, 60, 80, 100, 125, 150, 200, 350,
500 mM KCl) yielding ten fractions. Samples were desalted by C18
step chromatography (OASIS 60mg C18; waters.com), followed by
TiO2 affinity chromatography (10 u beads; glsciences.com) using
3 mg TiO2 beads per fraction in 100 ul 0.1% TFA, 50% acetonitrile
(ACN), where 1 M lactic acid was used to suppress non-specific
binding. Phosphopeptides were eluted with 50 mM KH2PO4 pH
10.5 (pH adjusted with NH4OH), immediately neutralized with
5% formic acid, 50% acetonitrile, and lyophilized. Peptide frac-
tions were resuspended in 0.1% FA and analyzed by LC-MS/MS.
Peptides not binding to TiO2 (flow through fraction) were desalted
(OASIS 60 mg C18; waters.com), lyophilized and protein concen-
tration determined by micro BCA assay (piercenet.com). Peptide
fractions were resuspended in 2% ACN, 0.1% FA, and analyzed by
LC-MS/MS.
PEPTIDE IDENTIFICATION AND QUANTIFICATION BY LC-TANDEMMS
LC-MS/MS was performed essentially as previously described
(33, 34). Two (A549) or three (H358) LC-MS/MS experiments
were performed for each fraction (1 fraction for pY, 10 frac-
tions for SCX/TiO2, and 10 fractions for SCX/total peptide).
Proteins were identified from survey and product ion spectra
data, using the Paragon algorithm of ProteinPilot [v4.0; (35)] and
GPM [(36) v2.2.1]. Two missed tryptic cleavages were allowed
and posttranslational modifications considered included cysteine
derivitization, STY phosphorylation, deamidation, carbamylation,
oxidation, and SILAC labels. Database searches used the human
UniProt FASTA database (10-2012; 70,391 sequences including
common contaminants). When multiple protein isoforms were
identified, Protein Pilot allowed only peptides specific to each
detected isoform to be used, which factored in ion counts for
weighting in the protein ratio calculation (37). Parsimony of pro-
tein results was assured by rigorous protein inference with the
ProGroup algorithm. Protein identification complied with the
guidelines of Bradshaw et al. (38) where two or more unique
isoform-specific peptides were required for inclusion. False dis-
covery rates of phosphotyrosine peptide capture experiments were
<1%. False positive rates for the high complexity TiO2 and total
peptide assignments ranged between 1.4 and 0.8%. For statisti-
cal analysis we required four or more peptides with individual
peptide assignments at >95% confidence. Phosphopeptide peak
areas were normally distributed by log10+ 1 conversion followed
by paired t -test. Phosphopeptides sites identified four or more
times are listed in Table S2 in Supplementary Material and coordi-
nate changes in phosphopeptide abundance between H358 and
A549 models were observed for 73 unique sites are listed in
Table S3 in Supplementary Material. Fifty-eight protein abun-
dance changes were coordinately associated with H358 and A549
trans-differentiation, with two or more unique peptides also at
95% peptide ID confidence are listed in Table S4 in Supplementary
Material. Co-correlation of overlapping peptides from skipped
cleavage and multiple charge states were used to further reduce
false discovery rates and correctly bin previously defined bench-
mark peptides from E-cadherin, vimentin, and fibronectin to their
respective epithelial or mesenchymal cell states.
FUNCTIONAL ANALYSIS AND PERFORMANCE PARAMETERS
A schema for the statistical and categorical analysis of pro-
tein, phosphopeptide, and RNA transcript data is provided in
Figure 1. Changes in the abundance of proteins, phosphopep-
tides, and RNA transcripts were compared between fractions,
experiments, and models where membership within specific sig-
naling networks only was established using two or more inde-
pendent lines of evidence. Cross-correlation between two inde-
pendent isogenic KRas models was used to reduce noise and
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FIGURE 1 | Marker expression in H358 and A549 isogenic mesenchymal
trans-differentiation models. (A) Immunoblot staining for E-cadherin, CD44,
vimentin, and actin (control) in the H358-dox-TGFβ model in epithelial (−dox)
or mesenchymal (+dox) states (5 days and ~180 days on doxycycline).
(B) Deconvoluted fluorescence microscopy image for CD44 (green) and
E-cadherin (red) in the H358-dox-TGFβ model in epithelial (−dox) or
mesenchymal (+dox) states. (C) H358 cells induced to express TGFβ for
14 days (bottom panels) show increased aldefluor activity, a marker of
aldehyde dehydrogenase activity and stemness, relative to control cells (top
panels), as measured by FACS. (D) Immunoblot staining for fibronectin,
E-cadherin, vimentin, and GAPDH (control) in the A549 cell in the presence or
absence of exogenous TGFβ (10 ng/ml) for 7 or 14 days. (E) A workflow
schema for RNA, protein, phosphopeptide abundance measurement, and
cross-correlation.
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reduce false positives. Proteins, phosphopeptides, and RNA tran-
scripts differentially expressed between EMT-like cell states were
grouped by function using literature, gene-set enrichment (GSEA)
(v14; broadinstitute.org/gsea), Gene Pattern (v3.8.1; broadin-
stitute.org/cancer/software/genepattern), DAVID2, and Ingenuity
pathway prediction (IPA; ingenuity.com). In the functional illus-
trations of complexes modulated during EMT, proteins were
assembled by protein–protein contacts [BioGrid; thebiogrid.org/
(39); STRING; string-db.org] and further grouped manually by
biological systems or “machines.” The function of individual
peptide phosphosites was evaluated using PhosphoSite [phos-
phosite.org; (40)] and published literature. Venn overlaps were
calculated using (bioinformatics.psb.ugent.be/webtools/Venn/).
REPORTER PLASMID TRANSFECTION
SuperTOP plasmid is a TCF–LEF responsive promoter driving
expression of luciferase (addgene.com). The control superFOP
contains mutated TCF/LEF promoter binding sites and serves
as a negative control. The TK-renilla plasmid serves to normal-
ize for DNA uptake. Plasmids were isolated from DH5a E. coli
using an endotoxin-free isolation (qiagen.com). H358-dox-TGFβ
cells were plated into 12 well plates (~2× 105 cells/well). Super
TOP, super FOP, and control Renilla plasmids (promega.com),
were transfected using Lipofectamine 2000 (lifetechnologies.com)
and reporter assays conducted as defined by the manufacturer
(promega.com). After normalization to Renilla control signal,
TOP and FOP data were expressed in relative light units (RLUs).
IMMUNBLOT AND IMMUNOFLUORESCENCE
Gel electrophoresis and immunoblot of H358 and A549 cell
extracts were performed under standard conditions using ECL
Plus Western Blotting Substrate (piercenet.com) using vimentin
(1:5000 dilution; bdbiosciences.com) and E-cadherin antibodies
(1:1000 dilution; cellsignal.com). Immunofluorescence was per-
formed under standard conditions using β-catenin (1:100 dilu-
tion), E-cadherin (1:200 dilution), and CD44 antibodies (1:400
dilution), all from Cell Signaling Technologies (cellsignal.com)
with DAPI staining. Cells were imaged using a Zeiss Axiovert
inverted fluorescence microscope at 60×magnification.
RESULTS
CHARACTERIZATION AND VALIDATION OF H358 AND A549
MUTANT-KRas MODELS
Two KRas mutant adenocarcinoma NSCLC cell lines H358 and
A549 were used as model systems to molecularly define tran-
scriptional and epigenetic reprograming following mesenchymal
trans-differentiation. H358 and A549 cells can spontaneously gen-
erate populations of CDH1high/CD44low and CDH1low/CD44high,
with epithelial and mesenchymal-like phenotypes, respectively
(41). Spontaneous inter-conversion has been previously reported
(42, 43). H358 contain relatively rare (estimated at ~2–4%)
CDH1low/CD44high cells while A549 are typically a more mixed
population of each phenotype. As such, all H358 experiments
were initiated from epithelial CDH1high/VIMlow clones with
2http://david.abcc.ncifcrf.gov/
predominant epithelial cell-junctions, from which subsequent
H358/dox-TGFβ clones were derived. Doxycycline (0.5µg/ml)
induction of transgene expression, a constitutively active form
of TGFβ1 (37), was verified by immunoblot and was shown to
correctly modulate EMT marker expression (CDH1low, CD44high,
and VIMhigh) as shown in Figure 1A. Fluorescence microscopy
(Figure 1B) showed loss of E-cadherin membrane localization
and gain of CD44 expression in H358/dox-TGFβ cells relative to
the minus dox control. Multiple H358/dox-TGFβ clones exhibited
correct isogenic mesenchymal trans-differentiation and in con-
trast vector control cells remained epithelial in the presence of
doxycycline (24). Similarly, the percentage of aldefluor positive
cells, a marker of aldehyde dehydrogenase activity and putative
stemness, was increased after mesenchymal trans-differentiation
with TGFβ for 14 days. The percentage of aldefluor positive cells
was 6.2% in the −dox control H358 cells and 16.8% in the +dox
H358/TGFβ producing cells (Figure 1C). A549 cells were anti-
CD44 antibody counter selected using magnetic beads into a
CD44low starting epithelial population, which was subsequently
induced with TGFβ (10 ng/ml) to yield a uniformly mesenchymal
cell population after 14 days. This allowed a more direct compar-
ison of the CD44low starting population with the TGFβ-induced
mesenchymal population, which became CD44high. Immunoblot
for fibronectin, E-cadherin, and vimentin confirmed an EMT
transition after 7 and 14 days exposure to TGFβ in A549 cells
(10 ng/ml; Figure 1D). EMT occurs in H358 and A549 epithelial
CDH1+/CD44low subclones exposed to TGFβ over a prolonged
period.
INTEGRATION OF RNA, PROTEIN, AND PHOSPHOPROTEIN EMT
STATE-SPECIFIC MEASUREMENTS
In order the globally assess differences between isogenic epithe-
lial and mesenchymal cell states, we measured RNA, protein, and
phosphorylation changes as outlined in Figure 1E. RNA-Seq (44)
was performed where non-zero ratios with RSEM reads≥5 for any
condition are listed in Table S1 in Supplementary Material (20,443
genes). Correlation between biological replicate RNA-Seq samples
was r2= 0.90 and r2= 0.84 for H358 and A549 models, respec-
tively (Figure 2A). Protein and phosphopeptide changes between
epithelial and mesenchymal cell states were measured using SILAC
labeling (31) in H358 and A549 TGFβ-treated or control. Analy-
sis of RNA and protein abundance (Figure 2B) confirmed the
gain of vimentin (VIM), fibronectin (FN1), and loss of keratin-8
(KRT8) and S100A6, expected RNA and protein changes occurring
with mesenchymal trans-differentiation. We focused on changes in
RNAs encoding transcription regulators, where 82 transcripts were
coordinately regulated in comparing mesenchymal and epithelial
cell states for both isogenic H358 and A549 models (Figure 2C).
FUNCTIONAL ANNOTATION OF TRANSCRIPTION AND EPIGENETIC
NETWORKS
Functional association with RNA abundance changes was assessed
by GSEA. As expected multiple signatures associated with KRas
transformation, stemness, and mesenchymal trans-differentiation
were significantly enriched (Table S5 in Supplementary Mater-
ial), with normalized enrichment score (NES) p-value <0.05 and
the false discovery rate (FDR) q-value <0.05. Similarly pathway
www.frontiersin.org December 2014 | Volume 4 | Article 344 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Haley et al. Epigenetic and transcription networks in NSCLC EMT
C
H358 model
A549 model
A
Gene 
Symbol
Gene 
H358    
log2 M:E
 Gene 
A549    
log2 M:E
Protein 
H358   
log2 M:E
Protein 
A549   
log2 M:E
ACTN1 0.67 1.15 0.63 1.36
ALDH3A2 -1.23 -1.04 -1.55 -1.55
ANXA6 3.84 1.45 0.44 0.94
CALU 1.34 1.20 1.18 1.52
CDH1 -2.59 -5.04 -1.67 nd
ENO2 0.93 1.25 1.11 0.70
FN1 2.12 2.06 2.46 2.94
KRT8 -2.36 -1.79 -4.10 -0.50
PLOD2 0.72 2.57 1.65 1.50
S100A6 -1.03 -0.93 -1.21 -3.41
TGFBI 1.58 1.73 2.70 2.65
TLN1 1.10 1.46 0.80 0.79
TPM1 0.57 1.18 1.38 2.59
VIM 2.15 0.81 3.15 1.74
ZYX 1.12 1.15 1.03 1.39
B
Gene Symbol Entrez Gene Name
H358 
M1:E
H358 
M2:E
A549 
M1:E
A549 
M2:E
ABLIM3 actin binding LIM protein family, member 3 1.14 1.33 1.43 1.38
ANKRD2 ankyrin repeat domain 2 -3.58 -2.58 -2.30 -2.66
ATXN1 ataxin 1 1.16 1.29 2.32 2.24
BCL11A B-cell CLL/lymphoma 11A 2.54 2.64 >5 >5
BNC2 basonuclin 2 1.90 2.10 1.31 1.29
C19orf33 chromosome 19 open reading frame 33 -1.06 -0.85 -1.63 -1.52
CREB3L1 cAMP responsive element binding protein 3-like 1 2.98 3.15 1.90 1.54
CUX2 cut-like homeobox 2 >5 >5 3.12 2.58
DLX2 distal-less homeobox 2 0.66 1.06 2.32 1.58
DPF3 D4, zinc and double PHD fingers, family 3 1.98 2.02 >5 >5
EBF1 early B-cell factor 1 3.49 3.54 1.40 1.60
EBF4 early B-cell factor 4 7.55 7.66 1.16 0.85
EHF ets homologous factor -2.32 -2.25 -3.32 -4.54
ELF3 E74-like factor 3 -4.96 -4.39 -2.36 -2.52
ELL2 elongation factor, RNA polymerase II, 2 0.94 1.06 1.93 1.87
ERG v-ets erythroblastosis virus E26 oncogene homolog >5 >5 >5 >5
FANK1 fibronectin type III and ankyrin repeat domains 1 1.05 1.20 1.03 0.55
FLI1 Friend leukemia virus integration 1 >5 >5 4.75 4.00
FOXE1 forkhead box E1 -1.19 -0.94 -1.27 -1.08
FOXO4 forkhead box O4 2.20 2.60 1.09 0.70
FOXQ1 forkhead box Q1 3.91 4.12 2.89 2.68
GATA2 GATA binding protein 2 -2.17 -2.23 -2.68 -2.68
GLI3 GLI family zinc finger 3 0.98 1.16 7.79 7.78
GLIS1 GLIS family zinc finger 1 5.75 5.17 4.32 3.81
GPER G protein-coupled estrogen receptor 1 -1.04 -0.57 -3.00 -3.00
GRHL1 grainyhead-like 1 -1.71 -1.33 -1.44 -2.64
HDAC5 histone deacetylase 5 1.74 1.84 2.07 1.94
HIVEP2 HIV type I enhancer binding protein 2 1.01 1.24 1.10 0.99
HIVEP3 HIV type I enhancer binding protein 3 1.25 1.47 1.66 1.57
HLF hepatic leukemia factor -1.60 -1.17 -4.48 -3.89
HLX H2.0-like homeobox 1.43 1.54 1.04 0.92
HNF1A HNF1 homeobox A -1.32 -0.77 -3.70 -3.84
HR hairless homolog -1.42 -1.61 -5.16 -4.71
ID4 inhibitor of DNA binding 4 -2.57 -2.36 -1.23 -1.11
JAZF1 JAZF zinc finger 1 4.22 4.54 1.04 1.09
KCNIP3 Kv channel interacting protein 3, calsenilin 2.24 2.46 0.69 1.61
KLF5 Kruppel-like factor 5 -1.84 -1.76 -1.68 -1.67
LHX1 LIM homeobox 1 3.06 3.27 1.08 1.15
MNX1 motor neuron and pancreas homeobox 1 -1.81 -1.89 -1.73
MXI1 MAX interactor 1 1.26 1.47 1.63 1.35
NKX6-1 NK6 homeobox 1 1.21 1.91 3.58 3.91
NOVA1 neuro-oncological ventral antigen 1 1.04 1.46 2.04 1.87
NR4A1 nuclear receptor subfamily 4, group A, member 1 2.29 2.32 0.98 1.09
NR4A3 nuclear receptor subfamily 4, group A, member 3 1.72 2.21 1.92 1.96
NR5A2 nuclear receptor subfamily 5, group A, member 2 -1.83 -1.67 -1.07 -0.77
OSR2 odd-skipped related 2 -2.32 -2.68 -1.00 -1.50
PAX6 paired box 6 1.14 1.52 1.33 1.28
PPP1R13L protein phosphatase 1, regulatory subunit 13 like 1.51 1.63 0.91 1.11
PRDM13 PR domain containing 13 -1.13 -0.74 -2.00 -3.00
PROX2 prospero homeobox 2 1.65 1.65 1.42 1.42
RAI14 retinoic acid induced 14 0.90 1.07 1.53 1.47
RNF208 ring finger protein 208 -2.50 -3.31 -1.13 -1.81
RORA RAR-related orphan receptor A 0.98 1.51 1.00 2.17
SAMD4A sterile alpha motif domain containing 4A 1.61 1.77 1.55 1.65
SHOX2 short stature homeobox 2 0.98 1.17 1.75 1.98
SMAD9 SMAD family member 9 1.86 2.03 2.44 2.75
SMARCD3 SWI/SNF related, subfamily d, member 3 2.72 2.69 0.98 1.18
SOX2 SRY -2.17 -1.87 -1.32
SP110 SP110 nuclear body protein 0.88 1.06 1.24 1.11
SPDEF SAM pointed domain containing ets transcription factor -2.64 -2.32 -6.59 -6.59
SREBF1 sterol regulatory element binding transcription factor 1 -1.28 -1.14 -1.46 -1.68
STOX1 storkhead box 1 -1.51 -1.21 -0.89 -1.12
SUPT3H suppressor of Ty 3 homolog 1.33 1.62 1.19 1.17
TANC2 tetratricopeptide repeat 2 0.87 1.14 1.64 1.62
TCF4 transcription factor 4 1.05 1.26 1.83 1.95
TFAP2C transcription factor AP-2 gamma -2.47 -2.19 -2.10 -2.15
TGFB1I1 transforming growth factor beta 1 induced transcript 1 1.57 1.75 2.00 1.95
TP63 tumor protein p63 -1.79 -1.68 -4.83 -4.42
TRANK1 tetratricopeptide repeat and ankyrin repeat containing 1 1.92 2.20 1.65 1.65
VGLL3 vestigial like 3 (Drosophila) 1.60 1.84 1.94 1.89
YBX2 Y box binding protein 2 -1.80 -1.83 -3.75 -1.43
YPEL4 yippee-like 4 (Drosophila) 5.07 5.44 1.58 2.00
ZEB1 zinc finger E-box binding homeobox 1 3.61 3.78 1.01 1.04
ZMAT1 zinc finger, matrin-type 1 4.33 4.67 3.16 2.58
ZNF167 zinc finger protein 167 0.94 1.11 1.05 1.18
ZNF25 zinc finger protein 25 1.53 1.63 1.30 1.22
ZNF275 zinc finger protein 275 1.00 1.12 0.79 1.01
ZNF296 zinc finger protein 296 -1.33 -0.83 -2.17 -1.67
ZNF469 zinc finger protein 469 2.00 1.98 1.70 1.65
ZNF544 zinc finger protein 544 -1.18 -0.83 -1.57 -1.54
ZNF575 zinc finger protein 575 1.35 1.63 1.14 1.14
ZNF860 zinc finger protein 860 -1.92 -1.52 -1.80 -1.80
FIGURE 2 | (A) Regression analysis of duplicate mesenchymal RNA-Seq samples expressed at a ratio to the mean epithelial control for both H358 and A549
models (greater than twofold changes are indicated in black). (B) Concordant RNA and protein changes for both isogenic H358 and A549 models.
(C) Transcription associated RNA transcripts with differential abundance between epithelial and mesenchymal cell states in both H358 and A549 models.
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prediction analysis predicted activation of TGFβ signaling (45),
and inhibition of DKK1 and SMAD7 signaling. These findings fur-
ther served as validation benchmarks for the GSEA and pathway
prediction approaches. Similarly benchmark RNA expression val-
ues for transcriptional regulators, which can induce EMT [Snail,
Slug, Twist, and Zeb (9, 46–48)] were markedly increased in a
model dependent manner (Table S6 in Supplementary Material).
Transcriptional signatures surrounding LEF1, NFκB, and BMI1
were highly enriched in datasets comparing H358 and A549
epithelial and mesenchymal-like cell states using GSEA and/or
pathway prediction analysis (Table 1). We considered other pre-
dicted activated or inhibited nodes common to both KRas trans-
differentiation models. Pathway prediction analysis was used to
model signaling activation or inhibition based on transcription
factor response. Table 2 summarizes pathway state based on H358
and A549 RNA-Seq datasets. Expected activation or Snail (H358),
Twist (A549), and STAT pathways [H358 and A549 via increased
IL11 and IL6; (23, 49)] was expected but highlight model hetero-
geneity, even within closely related NSCLC systems. Interestingly,
RNA expression correlated the mesenchymal state with KDM5B,
SMARCA4, and EGR1 pathway activation, and Myc/Max, SIN3A,
and SPDEF pathway inhibition.
ALTERED TCF/LEF AND NFκB NETWORKS WITH THE MESENCHYMAL
CELL STATE
Canonical Wnt signaling leads to the nuclear translocation of β-
catenin and the activation of TCF and LEF family transcription
factors, which in turn promote pro-survival gene expression pro-
grams. The activation of the Wnt/β-catenin/TCF–LEF axis has
been implicated in epithelial mesenchymal transition and metasta-
tic behavior (50, 51). GSEA correlations predict LEF1 pathway
activation in the mesenchymal state (Table 1). Figure 3A shows
Table 1 | RNA changes correlating with gene-set enrichment (GSEA) signatures and/or pathway prediction analysis (IPA) for (A) Wnt/LEF1,
(B) NFκB, and (C) BMI1 signaling networks in H358 and A549 KRas NSCLC models comparing isogenic epithelial and mesenchymal cell states.
Node Tool Cell
model
State GSEA dataset NAME Size NES NOM
p-value
FDR
q-value
(A)
Wnt GSEA A549 Epi LEF1_UP.V1_DN 186 1.62 0.000 0.011
H358 178 1.66 0.000 0.013
IPA IPA transcription regulator IPA predicted
activation state
Reg.
z-score
p-Value
overlap
H358 Mes TCF12 Activated 1.45 0.040
A549 0.87 0.046
H358 WISP2 Inhibited −4.26 0.021
A549 −2.31 0.000
(B)
NFkB GSEA A549 Epi HINATA_NFKB_TARGETS_DN 23 1.30 0.102 0.243
H358 23 1.99 0.006 0.005
A549 Mes HINATA_NFKB_TARGETS_UP 91 −1.85 0.000 0.013
H358 87 −1.53 0.004 0.121
A549 SCHOEN_NFKB_SIGNALING 34 −1.57 0.010 0.149
H358 33 −1.44 0.054 0.182
IPA IPA transcription regulator IPA predicted
activation state
Reg.
z-score
p-Value
overlap
H358 NFKB1 Activated 0.61 0.002
(C)
BMI GSEA A549 Epi BMI1_DN.V1_DN 141 1.50 0.000 0.023
H358 126 1.54 0.000 0.017
A549 Mes BMI1_DN.V1_UP 145 −1.49 0.000 0.032
H358 142 −1.66 0.000 0.007
A549 Epi BMI1_DN_MEL18_DN.V1_DN 145 1.54 0.000 0.016
H358 129 1.66 0.000 0.015
A549 Mes BMI1_DN_MEL18_DN.V1_UP 144 −1.82 0.000 0.002
H358 141 −1.83 0.000 0.001
A549 Mes PRC1_BMI_UP.V1_DN 184 −1.30 0.023 0.119
H358 158 −1.41 0.004 0.060
A549 WIEDERSCHAIN_TARGETS_BMI1_PCGF2 57 −1.49 0.011 0.213
H358 56 −1.56 0.009 0.104
Individual GSEA signatures are defined in detail at http:// www.broadinstitute.org/ gsea/ msigdb/ index.jsp. Statistical significance is denoted by values in italics.
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Table 2 |Transcription pathway prediction (IPA) based on differential
RNA expression between mesenchymal and epithelial cell states for
both A549 and H358 models.
Model Upstream
regulator
Predicted
activation
state
Activation
z-score
p-Value of
overlap
H358dT E2F6 Inhibited −2.55 0.002
A549 E2F6 −1.85 0.002
H358dT EGR1 Activated 2.95 ns
A549 EGR1 Activated 3.14 ns
H358dT ESRRA Inhibited −2.30 0.006
A549 ESRRA Inhibited −3.33 0.009
H358dT ETS1 1.45 0.029
A549 ETS1 1.92 ns
H358dT FOXM1 Inhibited −2.70 0.014
A549 FOXM1 −1.19 0.023
H358dT KDM5B Activated 3.52 0.000
A549 KDM5B Activated 2.27 0.000
H358dT MAX Inhibited −3.20 0.012
A549 MAX Inhibited −2.18 0.002
H358dT MYC Inhibited −3.76 0.000
A549 MYC Inhibited −2.16 0.000
H358dT NRF1 −1.17 0.004
A549 NRF1 Inhibited −3.03 0.024
H358dT PPARGC1B −0.96 0.003
A549 PPARGC1B −0.61 0.046
H358dT RUVBL1 −1.06 0.001
A549 RUVBL1 −1.92 0.000
H358dT SIN3A Inhibited −2.33 ns
A549 SIN3A Inhibited −2.33 ns
H358dT SMAD7 Inhibited −2.02 ns
A549 SMAD7 −1.87 ns
H358dT SMARCA4 Activated 2.67 ns
A549 SMARCA4 Activated 2.42 ns
H358dT SNAI1 Activated 2.32 0.053
H358dT SPDEF Inhibited −4.24 ns
A549 SPDEF Inhibited −2.92 0.027
A549 STAT3 Activated 2.10 ns
H358dT STAT6 1.93 ns
H358dT TP53 Activated 3.07 0.000
A549 TP53 Activated 3.07 0.000
H358dT TRIM24 Activated 2.93 ns
A549 TRIM24 1.76 ns
H358dT TSC22D1 Activated 2.24 ns
A549 TSC22D1 Activated 2.24 ns
H358dT TWIST2 1.76 ns
A549 TWIST2 Activated 2.19 0.032
H358dT USF1 1.88 ns
A549 USF1 1.89 ns
H358dT WT1 0.84 0.003
A549 WT1 1.02 0.001
H358dT XBP1 Activated 6.62 0.001
A549 XBP1 1.24 0.000
(Continued)
Model Upstream
regulator
Predicted
activation
state
Activation
z-score
p-Value of
overlap
H358dT YY1 1.77 0.003
A549 YY1 1.56 0.006
Expected marker genes, Snail for H358 and Twist2 for A549, served as internal
benchmarks. Activation of transcriptional regulators KDM5B, EGR1, SMARCA4,
TP53,TSC22D1, inhibition of ESRRA, MYC/MAX, SIN3A, and SPDEF were corre-
lated with both H358 and A549 mesenchymal states. TGFβ1, the EMT inducer,
served as an internal control.
GSEA plots of genes down-regulated by overexpression of LEF1 in
epithelial DLD1 cells (52), positively correlating with the epithe-
lial cell state. Correlations between the H358 and A549 RNA
abundance changes and LEF1 gene signatures were statistically
significant (p< 0.0001 and FDR q-value <0.02; Table 1A). The
top 20 positively and negatively correlated genes were identi-
fied and heat mapped for H358 (Figure 3B; control and TGFβ
duplicate samples) and for A549 (Figure 3C; control and TGFβ
duplicate samples). The data suggested TCF/LEF1 signaling were
up-regulated in EMT-derived mesenchymal lung tumor cells. We
asked whether EMT state in H358 or A549 cells might alter the
abundance of RNA transcripts encoding components of the Wnt
signaling pathway itself, where log2 ratios are shown for duplicate
samples comparing 44 Wnt pathway components between mes-
enchymal and epithelial states (Figure 4A). Both positively acting
and negatively acting Wnt pathway encoded RNAs were observed.
The Wnt pathway positive regulators TCF4/TCF7L1/LEF1 and
WNT5A/5B were found to be up-regulated in either H358 or A549
mesenchymal cell states, while the negative regulators DKK1 and
NDK2 were down-regulated in mesenchymal cell states.
Nuclear β-catenin localization has been shown to correlate with
neoplastic transformation and cancer patient outcome (53). In
normal epithelial cells β-catenin forms a complex with α-catenin
and E-cadherin on the inner side of the plasma membrane, impor-
tant for cell–cell interaction. By immunofluorescence microscopy,
we observed that β-catenin was localized at cell–cell-junctions
on the inner side of the plasma membrane in the epithelial cell
state, as expected (Figure 4B; top panels). In the mesenchymal cell
state, β-catenin staining was lost from the cell membrane, with
expected (54) diffuse cytoplasmic and speckled nuclear staining
(Figure 4B; bottom panels). We asked whether signaling through
the Wnt/β-catenin pathway might show a change in activity
between epithelial and mesenchymal lung states. H358 cells were
transfected with TCF promoter–reporter plasmid (sTOP),measur-
ing TCF/LEF dependent transcription, or control (FOP) plasmid
with mutated TCF/LEF binding sites. A control TK-renilla plasmid
was used to control for transfection efficiency. Triplicate biologi-
cal experiments were performed, each run in triplicate, which were
normalized to the TK-renilla control and averaged (Figure 4C).
We observed the signal from the TCF/LEF reporter was increased
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FIGURE 3 | (A) Correlation of H358 and A549 EMT regulated genes with
the LEF1 signature from LEF1 over-expressing epithelial DLD1 cells (from
GSE3229). Normalized enrichment score (NES) was 2.63, nominal
p-value, FDR q-value, and FWER p-value were <0.001. (B) The top 20
positively and negatively correlated genes were identified and heat
mapped for H358 (B) control [0; A, B] and TGFβ [180; A, B] duplicate
samples) and (C) for A549 (control [Cntrl; LB13, LB16] and TGFβ [TGFb;
B11, B12] duplicate samples).
8.5-fold in the mesenchymal state relative to the epithelial state
in all experiments (p= 0.02). Similar findings were observed fol-
lowing serum removal for 24 prior to transfection and maintained
for 48 h following transfection, where TCF/LEF reporter activ-
ity was increased in the mesenchymal state 6.1-fold (p= 0.004).
The mutated control reporter showed minimal activity relative
to TCF [p= 0.02 in serum and p= 0.002 in serum-free condi-
tions (SFM)]. The use of LEF signatures and TCF/LEF reporter
data serves in part to validate the informatics approach, further
supported by correlation with expected gene signatures (Table
S5 in Supplementary Material) for TGFβ, stem cell, and KRas
pathways.
Gene-set enrichment and pathway prediction analysis of RNAs
altered in abundance with mesenchymal trans-differentiation,
indicated potential activation of the NFκB pathway, particu-
larly in A549 (Table 1B; Figure 5A). The Hinata NFκB sig-
nature was derived from normal keratinocytes over-expressing
NFKB1 and RELA (52). The Schoen NFκB signature reflects genes
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A B
C
H358/doxTGFβ
H358-dox
Name H358-1 H358-2 A549-1 A549-2
APC2 0.74 1.34 1.22 1.44
AXIN2 -1.50 -1.34 -0.24 0.18
BTRC 0.68 0.93 0.07 0.07
CCND1 -1.21 -1.00 -0.49 -0.45
CDH1 -2.70 -2.47 -5.22 -4.86
CREBBP -1.28 -1.00 0.23 0.24
CSNK1E 1.04 1.14 0.98 0.84
CTBP1 -1.07 -0.91 0.21 0.28
CTBP2 -0.60 -0.37 0.00 -0.07
CTNNB1 0.52 0.72 0.07 0.03
DIXDC1 1.21 1.41 1.15 1.03
DKK1 -1.12 -0.91 -3.94 -3.91
DKK2 -2.13 -1.98 nd nd
DKK3 1.87 2.10 1.98 1.91
FBXW10 -1.88 -2.21 -0.57 -0.61
FN1 2.00 2.24 2.11 2.01
FOSB 1.65 1.83 -0.06 -0.35
FOSL2 -0.40 -0.23 1.04 1.05
FZD3 -1.03 -0.68 -0.81 -0.67
FZD5 -2.76 -2.48 -0.54 -0.68
FZD8 -0.59 -1.07 -0.71 -1.09
FZD9 -1.63 -1.63 -1.45 -1.32
JUN 0.93 1.18 0.87 0.81
JUNB 1.02 1.24 -0.50 -0.45
LEF1 >5 >5 nd nd
LRP5 -1.86 -1.71 0.25 0.16
LRP5L -2.07 -1.67 -0.74 -0.61
LRP6 0.36 0.54 0.04 -0.01
MMP7 -3.86 -3.01 -5.11
MYC 0.84 1.04 0.41 0.44
NKD2 -4.85 -4.54 -1.66 -2.00
PPARD 1.68 1.81 0.40 0.32
SFRP4 -1.58 0.42 -3.00 -3.32
SFRP5 nd nd -2.75 -2.17
SMAD3 -1.19 -1.03 0.38 0.37
TCF4 1.05 1.26 1.83 1.95
TCF7 1.73 1.91 -0.77 -0.93
TCF7L1 1.02 0.78 0.39 0.43
TCF7L2 0.45 0.62 -0.13 -0.18
WNT11 -1.46 -0.85 -2.81 -2.81
WNT2B 1.64 1.88 0.42 1.22
WNT5A 3.27 3.47 9.32 9.37
WNT5B 1.87 3.06 0.96 1.08
WNT7B -2.40 -2.17 -0.24 -0.34
β-catenin DAPI
FIGURE 4 | Nuclear translocation of β-catenin andTCF/LEF activation in
steady-state mesenchymal H358 cells expressing Wnt5A. (A) Heat map of
RNA abundance of Wnt signaling components and target genes in H358 and
A549 isogenic models (mesenchymal/epithelial; log2) from duplicate samples.
(B) Loss of membrane β-catenin localization and gain of punctate nuclear
localization in mesenchymal H358/dox-TGFβ cells. Top panels: H358 cells in
the absence of doxycycline. Bottom panels: H358/dox-TGFβ cells in a
mesenchymal-like state. Cells were labeled with β-catenin antibody (red) and
DAPI (blue) and imaged (60X). (C) Co-transfection of sTOP-TCF/LEF-luciferase
(“TCF”) or control FOP-luciferase (“Cntrl”) was used to measure the activity
of the TCF–LEF pathway. Renilla-luciferase was used to normalize transfection
efficiency. H358/dox-TGFβ cells, in the presence or absence of doxycycline,
were transfected and after 48 h luciferase measurements preformed under
standard conditions. Both steady-state serum and 24 h serum starvation
conditions (“-SFM”) were used with similar results. The y -axis units are
relative light units (RLU). The means of two independent experiments are
shown, each in triplicate, where the error bars reflect the standard error of the
mean.
down-regulated in mesenchymal-like A375 melanoma cells treated
with an NFκB inhibitor (55). The top 20 positively and negatively
correlated genes form the Hinata signature correlation were iden-
tified and heat mapped for A549 (Figure 5B). RNAs encoding
components of the pathway, notably IL1, TLR5, and TLR9, were
markedly increased in the mesenchymal state (Figure 5C). It is
beyond the scope of this study to fully define upstream signal-
ing pathways, which promote the transcriptional and epigenetic
changes observed in H358 and A549 models. However, network
predictions from RNA sequencing datasets, phosphoproteomic
analysis, and kinase activity immunoblots all suggest pronounced
activation of ERK1/2 (56, 57) and casein kinase-2 (CK2) and the
inhibition of glycogen synthase-3 (GSK3) protein kinase activi-
ties in both A549 and H358 mesenchymal states. Phosphorylation
of GSK3beta on the kinase activating site Y216 is reduced in
H358 mesenchymal cells (data not shown). The inhibition of
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B
A
Name H358-1 H358-2 A549-1 A549-2
CCL2 nd nd 3.64 3.41
CD40 2.36 2.56 -1.64 -1.39
EGFR 0.34 0.53 0.33 0.38
EGR1 0.92 1.14 -0.42 -0.42
HMOX1 1.19 1.30 0.29 0.19
IL8 0.44 0.58 5.89 5.67
IL1A 3.05 3.48 4.81 4.44
IL1B 1.10 1.10 5.39 5.08
IRAK2 0.91 1.05 1.05 0.88
IRF1 -1.31 -1.10 0.23 0.45
JUN 0.93 1.18 0.87 0.81
NFKB1 -0.79 -0.66 0.42 0.35
NFKB2 0.85 0.97 -0.42 -0.41
TIMP1 1.10 1.32 0.34 0.35
TLR1 0.93 1.12 -2.90 -3.18
TLR2 -1.17 -0.87 nd nd
TLR4 1.41 1.60 nd nd
TLR5 0.99 1.32 1.85 1.49
TLR7 0.75 0.84 0.04 1.40
TLR9 1.32 2.31 2.59 2.05
TNFAIP3 0.12 0.39 1.86 1.87
TNFRSF10D 1.64 1.82 -0.25 -0.30
TRAF2 -0.55 -0.22 -1.25 -1.35
TRAF6 1.41 1.59 0.09 0.03
C
A549/TGFβ
D
TCF NFkB
TCF-NFkB 
overlap
Gene 
H358
Gene 
A549
CTNNB1 0.62 0.05
EP300 -0.48 0.12
LYL1 0.36
MEN1 0.10 -0.11
NR4A1 2.30 1.03
PML 0.46 0.57
SUMO1 -0.12 0.17
UBC -0.31 0.33
FIGURE 5 | Activation of the NFκB pathway in mesenchymal H358.
(Continued)
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FIGURE 5 | Continued
(A) Correlation of A549 EMT regulated genes with the NFκB signature from
NFκB and RELA over-expression in keratinocytes (52). Normalized enrichment
score (NES) was −1.85, nominal p-value <0.001, FDR q-value 0.01. (B) The
top 20 positively and negatively correlated genes were identified and heat
mapped for A549, as defined in Figure 4. (C) Heat map of RNA abundance of
NFκB signaling components and target genes in H358 and A549 isogenic
models (mesenchymal/epithelial; log2). (D) Protein–protein overlaps between
TCF4 and NFκB protein interaction datasets from BioGrid, showing NR4A1 as
a common physical node between the two pathways.
FIGURE 6 | (A) Increased BMI target gene enrichment from RNA-Seq
datasets comparing differential RNA expression between H358 and A549 cell
states. Statistical significance (p<0.0001 and FDR q-value <0.04 was
observed. (B) The top 20 positively and negatively correlated genes were
identified and heat mapped for H358 and (C) for A549, with labels as defined
in Figure 3.
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GSK3 has been shown to stabilize Snail, which in turn increases
Zeb1 expression, while CK2 kinase activity has been correlated
with NFκB activation (58). Wnt5A is a transcriptional target of
NFκB, which is increased in the mesenchymal state in both H358
and A549 models. Wnt5A driven TCF/LEF targets are known to
include CD44 and Snail, further reinforcing the establishment
of the mesenchymal state. Interaction nodes between TCF/LEF
and NFκB pathways were mapped using protein–protein inter-
action data (BioGrid; Figure 5D). The orphan nuclear receptor
NR4A1/TR3/Nur77 was identified as an up-regulated common
component of the LEF1 and NFκB 1 protein–protein interac-
tion networks. NR4A1 showed coordinate regulation with redox
sensitive genes, e.g., TXNDC5, suggesting NR4A1 may regulate
oxidative stress as has been observed in pancreas cancer mod-
els (59). Low NR4A1 levels have been correlated with cisplatin
resistance (60). The elevated RNA abundance for NR4A1 in the
mesenchymal state, suggest mesenchymal-like tumor cells may be
more sensitive to cisplatin. Our previous studies have shown mes-
enchymal H358 and A549 cells are relatively resistant to EGFR (8,
61, 62) and IGF1R/IR (63) TKIs and to gemcitabine and paclitaxel,
while retaining sensitivity to cisplatin in vitro.
ALTERED TRANSCRIPTION AND EPIGENETIC NETWORKS
BMI1 is a component of the polycomb repressive complex (PRC1),
formed by complexes with heterochromatin adaptor family pro-
teins (e.g., CBX8). PRC1 functions as an inhibitor of transcrip-
tion during embryogenesis and in neoplastic transformation, as a
tumor suppressor. BMI1 is required for Twist mediated EMT (64).
Multiple GSEA signatures associated with changes in BMI1 tar-
get gene expression were observed (Table 2C), with the majority
showing stringent statistical significance (p< 0.05 and FDR q-
value <0.05). The BMI_DN and Wiederschain signatures reflect
genes up-regulated the stem-like medulloblastoma line DAOY
by knockdown of BMI1 with or without co-knockdown of the
polycomb ring finger gene PCGF2/Mel-18 (65). In contrast, the
PRC1_BMI signature (66) is derived by knockdown of BMI1 in
fibroblasts, cells of mesodermal origin, showed a reversed corre-
lation. The GSEA plots correlating BMI1 knockdown with the
H358 and A549 mesenchymal cell state are shown (Figure 6A).
The top 20 positively and negatively correlated genes were iden-
tified and heat mapped for H358 (Figure 6B) and for A549
(Figure 6C), suggesting altered regulation of the BMI1 pathway
with EMT in the two mutant-KRas NSCLC models. Interestingly,
the GSEA indicated better correlation with inhibition of BMI1 tar-
get genes with the mesenchymal cell phenotype. However, direct
analysis of up-regulated and down-regulated BMI1 target genes
showed enrichment in both H358 and A549 epithelial and mes-
enchymal cell states (Table S7 in Supplementary Material), which
also was observed by GSEA (anti-correlation) at lower statistical
stringency. These findings suggest additional factor(s) likely con-
tribute to BMI1 target gene recognition and/or the directionality
of regulation between epithelial and mesenchymal cell states. Non-
PRC1 components may modify the directionality BMI1 output, for
example, CtBP, E2F6, NFκB, and Cited2 (67).
Runx family transcription factors contain a conserved Runt
DNA binding domain and are developmentally regulated. RUNX2
and RUNX3 are overexpressed in the A549 and H358 models,
Target
Gene 
Symbol
H358 
M1:E
H358 
M2:E
A549 
M1:E
A549 
M2:E
CREBBP -1.28 -1.00 0.23 0.24
ETS1 0.06 0.25 0.99 1.03
FOS 0.64 0.68 -2.13 -1.93
HDAC5 1.74 1.84 2.07 1.94
HIF1A -0.87 -0.68 0.83 0.87
HIVEP3 1.25 1.47 1.66 1.57
JUN 0.93 1.18 0.87 0.81
KAT2B 2.19 2.25 0.81 0.76
RBM14 -0.99 -0.82 0.21 0.27
RUNX2 -0.08 0.11 3.33 3.44
SMAD3 -1.19 -1.03 0.38 0.37
SMURF2 -0.39 -0.14 0.85 0.80
STAT3 0.47 0.62 -1.35 -1.37
SUV39H1 -1.31 -1.25 -0.24 -0.36
DLG4 2.65 2.74 0.20 0.19
EZH2 -1.13 -0.98 0.29 0.26
NOTCH1 1.64 1.78 -0.92 -0.95
RUNX3 6.98 7.06 0.77 0.79
SMAD3 -1.19 -1.03 0.38 0.37
SMURF2 -0.39 -0.14 0.85 0.80
SP110 0.88 1.06 1.24 1.11
SUV39H1 -1.31 -1.25 -0.24 -0.36
RUNX2
RUNX3
FIGURE 7 | RNA expression ratios comparing H358 and A549
mesenchymal/epithelial cell states in duplicate. Complexes associated
with RUNX2 (top) and RUNX3 (bottom) are shown.
respectively. RUNX3, previously thought to function as a tumor
suppressor, has recently been associated with cancer progression
(68) and cooperative induction with NFκB of the inflammatory
cytokine IL23 (69). In NSCLC overexpression of RUNX2 has
been observed in comparisons of tumor and normal tissues and
was implicated with poor outcome (70). The overexpression of
exogenous RUNX2 also has been shown to promote EMT (71,
72), increase migratory and invasive behavior (73), and increase
expression of Twist and Slug, both of which are markedly increased
with EMT in the A549 background. We examined interaction
networks around RUNX2 and RUNX3, where proteins forming
direct contacts and potentially establishing signaling complexes,
are shown in Figure 7. In H358 RUNX3 RNA expression was
correlated with increased expression for potential protein–protein
interactors SP110, NOTCH1, DLG4, JUN, KAT2B, HIVEP3, and
HDAC5 and decreased expression and potential interaction with
EZH2, SUV39H1, RBM14, CREBBP, and SMAD3. This also was
associated with an increased SP110 phosphorylation of S256.
In A549, Runx2 expression correlated with increased KAT2B,
HIVEP3, ETS1, SP110, and HDAC5 expression and decreased
expression of STAT3 and FOS.
Multiple transcription factors associated with the maintenance
of the epithelial state were markedly decreased with EMT in both
models. Grainyhead-like 1 (GRHL1) RNA expression is decreased
in both mesenchymal models and GRHL2 is reduced in the H358
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Table 3 | Statistical analysis of phosphopeptide changes with EMT
state, from proteins specifically associated with transcriptional
function (where N ≥4).
Cell
model
Gene
symbol
Site N Peptide
log2 M:E
p-Value
H358 ARID1A S696 8 0.67 0.0001
A549 BAZ1B S1468 6 −0.20 0.0001
H358 BRD3 S263 4 1.06 0.0016
H358 CBX3 S95 17 0.70 0.0001
H358 CBX8 S191 4 −0.59 0.0036
H358 CTR9 S970 5 0.84 0.0001
A549 CTR9 T925 6 0.56 0.0009
H358 CTR9 T925 7 −0.05 0.0862
H358 DAXX S495 14 0.84 0.0001
H358 DPF2 S142 7 0.35 0.0009
H358 EAF1 S158, S165 5 1.12 0.0001
H358 FLII S856 4 0.50 0.0001
H358 FOXK1 S416, S420 17 0.45 0.0001
H358 FOXK1 S441, S445 6 0.02 0.0001
A549 HDAC1 S393 15 −0.35 0.0001
H358 HDAC1 S393 10 0.02 0.0008
A549 HDAC2 S394 22 −0.12 0.0001
H358 HDAC2 S394 7 0.31 0.0013
H358 HDAC2 S422, S424 18 0.36 0.0001
H358 HIRIP3 S125 12 0.01 0.0010
H358 HIRIP3 S223, S227 14 −0.23 0.0038
H358 HIRIP3 T84, S87 4 0.12 0.0022
H358 HIST1H1B S18 54 −1.98 0.0001
H358 HIST1H1E T18 46 −1.75 0.0001
H358 IRF2BP1 S384 8 0.50 0.0001
A549 IRF2BP1 S436 5 −0.05 0.0001
A549 IRF2BP2 S175 6 −0.97 0.0060
H358 IRF2BP2 S175 6 −0.83 0.0001
H358 LMO7 S1510 6 −3.39 0.0001
H358 MED1 T1051 7 −0.10 0.0151
H358 MEF2D S231 5 1.16 0.0001
A549 MYBBP1A S1267 6 −0.29 0.0001
H358 NCOR2 S956 23 1.01 0.0001
H358 PELP1 S481 11 0.55 0.0001
H358 PHC3 T609, S616 5 1.09 0.0017
A549 PNN S100 14 −0.33 0.0001
H358 PNN S100 45 0.63 0.0001
H358 PURB S101 7 0.56 0.0001
H358 PURB S304 15 0.53 0.0001
H358 RBM15 S670, S674 8 0.07 0.0001
A549 RBM15 T568 8 −0.02 0.0001
H358 RBM15 T568 4 0.18 0.0013
H358 SAFB S601, S604 10 0.96 0.0001
H358 SAFB S604 7 0.32 0.0002
H358 SMARCA5 S66 26 −0.48 0.0897
H358 SMARCC1 S328, S330 8 0.91 0.0001
H358 SNW1 S224, S232 12 0.22 0.0001
H358 SP110 S256 16 0.16 0.0001
(Continued)
Cell
model
Gene
symbol
Site N Peptide
log2 M:E
p-Value
H358 SSRP1 S437 57 0.04 0.0001
H358 SUDS3 S234, S237 13 0.07 0.0001
H358 TLE3 S263, S267 6 0.64 0.0002
H358 TRIM28 S19 34 0.52 0.0001
H358 TRIM28 S473 6 0.30 0.0001
H358 TRIM28 S33 6 0.19 0.0001
H358 YBX1 S165 4 0.59 0.0001
H358 YBX1 S167 16 0.58 0.0001
H358 YBX1 S174 10 0.67 0.0001
H358 YBX1 S176 4 0.63 0.0001
H358 YBX1 S2 5 0.24 0.0069
H358 ZC3H8 S77 4 1.19 0.0001
Data are expressed as the log2 ratio of mesenchymal/epithelial values (log2 M:E).
Log2 ratio values are colored where red denotes increased in the mesenchymal
state and green denotes decreased in the mesenchymal state.
model. GRHL2 and GRHL1 share ~70% homology and GRHL2
has been associated with the maintenance of an epithelial state
(74, 75), as a target repressed by Zeb1. Similarly transcription
factor AP-2 gamma (TFAP2C), a transcription factor associated
with estrogen receptor signaling in breast cancer (76), showed
reduced expression in the mesenchymal state. Emerging data
indicate TFAP2C is important for the normal luminal epithe-
lial differentiation (77) where knockdown promotes mesenchymal
transition (78). Conversely, overexpression of the TFAP2C cDNA
reduced CD44 expression, and high TFAP2C expression was cor-
related with response to neoadjuvant chemotherapy (79). EHF, an
ETS family transcription factor, also has been associated with an
epithelial differentiation program and EHF RNA expression was
decreased (74). Interestingly, the epithelial-specific splicing fac-
tors ESRP1 and ESRP2 (80) are markedly attenuated with EMT
in the H358 model, but their expression is absent in both epithe-
lial and mesenchymal A549 states, again indicating considerable
heterogeneity in EMT programs within closely related NSCLC
models. Finally,Odd-skipped related 2 (OSR2) is a Smad3/4 down-
regulated palate and limb developmental gene (81), reduced in the
both mesenchymal models.
Epithelial mesenchymal transition state was correlated with
statistically significant changes in site-specific phosphorylation
(Table 3). Several members of the BAF SWI/SNF complex
chromatin remodeling proteins were altered in their pattern of
site-specific phosphorylation dependent on EMT state. Notably
SMARCC1 showed increased phosphorylation at positions S328
and S330, and ARID1A was increased in phosphorylation at
position S696. CBX3/HP1γ is a chromatin remodeling factor
implicated in euchromatin silencing in embryonic stem cells (82)
and in transcription elongation by RNA polymerase II on hete-
rochromatic genes (83). CBX3/HP1γ has shown overexpression
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Table 4 |Time course of cell cycle regulator RNA expression, comparing H358 mesenchymal–epithelial RNA abundance (log2 ratios).
Gene symbol Name Time (h)
0 1 2 4 6 8 18 24 72 168 500 4500
BTG2 BTG family, member 2 0.00 −0.14 0.09 0.29 0.57 0.33 1.46 1.14 1.45 1.17 0.77 0.82
CCNE1 Cyclin E1 0.00 −0.12 −0.10 −0.22 0.11 0.10 −1.67 −0.79 −1.98 −3.35 −0.65 0.35
CDCA7L Cell division cycle associated 7-like 0.00 0.07 −0.01 −0.42 −0.23 −0.30 −1.48 −0.96 −3.14 −4.34 −1.91 −0.61
E2F1 E2F transcription factor 1 0.00 0.14 0.08 −0.34 −0.13 −0.24 −1.06 −0.64 −5.73 −6.26 −2.71 −0.77
E2F2 E2F transcription factor 2 0.00 0.06 0.09 −0.28 −0.22 −0.30 −1.69 −1.04 −4.77 −5.36 −3.68 −2.20
E2F8 E2F transcription factor 8 0.00 −0.03 0.11 −0.14 −0.11 0.01 −1.25 −0.91 −4.07 −6.14 −3.23 −0.48
MCM2 Minichromosome maintenance
complex component 2
0.00 0.12 0.06 −0.38 −0.04 −0.10 −1.15 −0.69 −3.89 −4.12 −2.10 −0.74
MCM4 Minichromosome maintenance
complex component 4
0.00 0.05 0.04 −0.26 −0.07 −0.13 −1.09 −0.68 −4.34 −4.56 −2.37 −0.94
MCM5 Minichromosome maintenance
complex component 5
0.00 0.08 0.03 −0.38 −0.11 −0.20 −1.12 −0.51 −3.87 −3.36 −2.03 −0.95
MCM6 Minichromosome maintenance
complex component 6
0.00 0.04 0.05 −0.23 −0.10 −0.15 −1.06 −0.49 −2.87 −3.89 −2.75 −0.84
RBL1 Retinoblastoma-like 1 0.00 −0.01 0.17 −0.30 −0.16 −0.15 −1.27 −0.84 −3.62 −2.92 −2.00 −0.71
TGFB1 Transforming growth factor, beta 1 0.00 0.61 0.94 1.10 1.92 2.00 2.80 2.90 3.69 4.82 3.25 4.63
Genes were selected based on expression in 6–8 or 18–24 h time bins. TGFβ1, the doxycycline-induced transgene, served as an internal control. Log2 ratio values
are colored where red denotes increased in the mesenchymal state and green denotes decreased in the mesenchymal state.
in NSCLC (84) as compared with normal adjacent tissue, and
expression was correlated with poor survival rate [p= 0.02; (85)].
Phosphorylation measurements also suggested EMT state may be
regulated in part by increased phosphorylation of CBX3/HP1 at
position S95 (p< 0.001) and likely S93 (p= 0.10; not shown) in
the central region between chromo and chromoshadow domains.
CBX3/HP1 functions as a transcriptional silencer through histone
H3 K9 interaction, where phosphorylation at S93, likely by PKA,
results in a reduction of CBX3/HP1 mediated silencing and tran-
scription elongation (86). Change in phosphorylation of CBX8,
a component of the PRC1 complex, at position S191 within the
atrophin-1 domain also was observed (Table 3). Phosphorylation
of HDAC2 was increased at positions S422 and S424 in the mes-
enchymal state. S422 and S424 are known CK2a sites, associated
with inhibition of deacetylase activity (87). S394 is also a CK2a
phosphosite increased in H358, decreased in A549. The reported
role S394 in activation (88) and inhibition (87) of HDAC2 may be
context dependent through as yet undefined factors.
The PAF1 complex protein CTR9/SH2BP1, which plays a role in
the maintenance of ESC pluripotency showed phosphosite regula-
tion at T925 (A549) and S970 (H358) (Table 3). Additional tran-
scriptional and epigenetic regulators were found to be modified
by phosphorylation, including NCOR2/SMRT, MEF2D, FOXK1,
BRD3, and the PRC1 component PHC3. Decreased phosphoryla-
tion of the bromodomain protein kinase BAZ1B/WSTF at position
S1468, increased phosphorylation of EAF1 at sites S158 and S165
were observed. The phosphorylation of TRIM28/KAP1 S473, likely
by CHK2, inhibits co-repression of CDKN1A/p21 (89), and may
contribute the observed attenuation of cell cycling. ZC3H8 func-
tions as a repressor of GATA3 and shows increased phosphoryla-
tion at position S77 in mesenchymal H358 cells, where GATA3 has
been associated with the TGFβ growth suppression response (90).
EARLY TRANSCRIPTIONAL EVENTS IN THE TRANS-DIFFERENTIATION
OF MUTANT-KRas NSCLC MODELS
We asked whether key transcription factors, highlighted by GSEA
correlations, might show coordinate early expression during mes-
enchymal transition. RNA samples were isolated from the H358
model following TGFβ induction at 0, 1, 2, 4, 8, 16, 24, 72 h, 7 days
(~168 h), 21 days (~500 h), and the long term/steady-state condi-
tion (>4500 h), and duplicate samples sequenced. TGFβ1 served
as an internal control, where expression was observed within 1 h
after addition of doxycycline.
The exchange of cell cycle inhibition with migratory and
invasive gene activation programs is a hallmark of metastable
mesenchymal trans-differentiation. Reduced RNA expression of
cell cycle activators and increased expression of inhibitors was
observed and served as a benchmark (Table 4). Early in the EMT
epigenetic reprograming, inhibition of E2F family, MCM family,
CCNE1 and CDCA7L gene products, and an increase in BTG2
expression was observed. This was accompanied by reduced phos-
phorylation of Histone H1B and H1E at positions S18 and T18,
respectively (Table 3). Both sites are cell cycle sensitive, where T18
is a known CDK1 and CDK2 site.
We then examined changes in RNA abundance for encoded
transcriptional and epigenetic regulators. We identified 81 tran-
scriptional and epigenetic regulators expressed at early time
points in primarily two time bins (6–8 and 18–24 h; Table 5).
ELF3, ATOH8, EAF2, MYC, IRX5, CITED2, and ID2 showed
relatively rapid repression ~8 h after induction, which was con-
tinued at later time points. ELF3 encodes an E74-like domain
transcription factor, which is epithelial-specific. FOXS1, STAT5A,
and HIC1 were increased at the early, continuing on to later
time points. By 18–24 h HR, FOXR2, SOX2, RORA, and VSX1
showed a decrease in RNA abundance, while FOXS1, DMBX1,
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Table 5 |Time course of transcription factor RNA expression, comparing H358 mesenchymal–epithelial RNA abundance (log2 ratios).
Gene
symbol
Name Time (h)
0 1 2 4 6 8 18 24 72 ~168 ~500 >4500
ARID5A AT rich interactive domain 5A
(MRF1-like)
0.00 −0.01 −0.22 −0.41 0.05 −0.04 0.42 0.98 1.04 1.20 1.05 1.33
ATF5 Activating transcription factor 5 0.00 0.26 0.19 −0.19 0.20 0.06 −1.06 −0.55 −1.32 −1.94 −0.52 −1.54
ATOH8 Atonal homolog 8 0.00 −0.12 −0.23 −1.06 −0.66 −0.78 −2.00 −2.35 −3.91 −3.64 −3.91
BHLHE22 Basic helix-loop-helix family, member
e22
0.00 −0.12 −0.16 −0.49 0.10 −0.14 −1.58 −0.64 −2.06 −2.08 −1.12 −2.22
BHLHE40 Basic helix-loop-helix family, member
e40
0.00 −0.26 −0.23 −0.49 −0.17 −0.02 1.22 1.30 2.04 1.89 0.81 1.42
CHAF1A Chromatin assembly factor 1,
subunit A
0.00 0.04 −0.01 −0.31 −0.09 −0.18 −1.34 −0.69 −3.72 −3.74 −1.96 −0.82
CHAF1B Chromatin assembly factor 1,
subunit B
0.00 0.14 0.08 −0.24 −0.07 −0.07 −1.17 −0.64 −4.07 −4.34 −2.64 −1.26
CITED2 Cbp/p300-interacting transactivator 2 0.00 0.24 −0.13 −0.61 −0.23 −0.50 −1.19 −0.76 −0.56 −0.57 −0.53 −1.23
CITED4 Cbp/p300-interacting transactivator 4 0.00 0.20 0.12 −0.41 0.06 0.22 1.73 1.45 2.53 3.83 2.27 −0.18
CREB3L1 cAMP responsive element binding
protein 3-like 1
0.00 0.01 0.12 −0.34 0.07 0.11 1.00 1.46 2.23 1.04 2.04 3.07
DMBX1 Diencephalon/mesencephalon
homeobox 1
0.00 −0.03 0.02 −0.25 −0.21 −0.11 1.84 1.92 3.07 3.31 2.24 1.66
DPF1 D4, zinc and double PHD fingers
family 1
0.00 −0.02 −0.24 −0.62 0.11 0.14 −1.04 −0.27 −1.58 −2.91 −0.50 −0.19
EAF2 ELL associated factor 2 0.00 −0.11 −0.41 −0.48 −0.53 −0.58 −1.43 −0.51 −0.65 −1.86 −2.36 −0.61
ELF3 E74-like factor 3 0.00 0.45 0.00 −0.95 −0.55 −0.93 −1.36 −1.46 −2.34 −1.32 −1.95 −4.68
ELK3 ELK3, ETS-domain protein (SRF
accessory protein 2)
0.00 −0.01 −0.04 −0.24 −0.01 −0.03 0.59 0.92 1.62 1.19 1.00 1.19
FOXR2 Forkhead box R2 0.00 −0.01 −0.04 −0.26 0.06 −0.03 −2.02 −1.13 −4.27 −3.89 −1.12 −1.18
FOXS1 Forkhead box S1 0.00 0.98 0.93 2.19 3.29 5.44 3.47 5.80 6.11
GPS2 G protein pathway suppressor 2 0.00 0.03 −0.08 −0.42 −0.03 −0.08 −1.18 −0.71 −1.03 −0.78 −0.07 −0.18
GRHL3 Grainyhead-like 3 0.00 0.24 0.23 −0.45 −0.06 0.17 −1.13 −0.54 −1.19 −1.07 −1.86 0.41
HIC1 Hypermethylated in cancer 1 0.00 0.26 0.27 −0.31 0.23 0.33 1.45 2.20 2.44 2.04 1.98 2.84
HR Hairless homolog 0.00 0.05 −0.06 −0.50 0.16 0.26 −2.39 −1.20 −2.06 −3.33 −2.27 −1.51
ID2 Inhibitor of DNA binding 2 0.00 0.27 0.16 −0.84 −0.48 −0.46 −1.69 −1.01 −1.11 −1.67 −2.65 2.24
ID3 Inhibitor of DNA binding 3 0.00 −0.06 −0.04 −0.64 −0.27 −0.37 −1.63 −1.07 −2.19 −3.75 −3.35 −0.86
ID4 Inhibitor of DNA binding 4 0.00 0.34 0.17 −0.53 −0.16 −0.29 −1.65 −1.58 −1.06 −0.86 −1.73 −2.46
ING3 Inhibitor of growth family, member 3 0.00 0.12 0.16 −0.29 −0.01 −0.08 −1.01 −0.59 −1.26 −1.21 −0.63 −0.68
IRF6 Interferon regulatory factor 6 0.00 0.01 −0.15 −0.36 −0.17 −0.17 1.20 1.25 2.48 1.55 0.42 0.61
IRX5 Iroquois homeobox 5 0.00 −0.09 0.02 −0.47 −0.23 −0.52 −1.25 −0.66 −1.39 −1.21 −1.84 −3.58
ISL1 ISL LIM homeobox 1 0.00 0.06 −0.15 0.06 0.17 0.21 −1.58 −0.41 −1.08 −1.63 −1.00 0.09
JDP2 Jun dimerization protein 2 0.00 −0.09 −0.14 −0.18 0.28 0.13 1.01 1.70 3.85 3.33 2.35 0.98
JUNB Jun B proto-oncogene 0.00 −0.09 0.03 −0.87 0.06 0.19 1.13 1.58 1.95 2.31 1.46 1.14
KDM5B Lysine (K)-specific demethylase 5B 0.00 −0.06 −0.20 −0.19 −0.12 −0.18 0.57 0.69 1.23 1.24 1.14 1.22
KDM6A Lysine (K)-specific demethylase 6A 0.00 0.02 −0.11 −0.13 −0.15 −0.20 −0.21 0.04 −1.15 −1.70 −1.17 −1.92
KDM6B Lysine (K)-specific demethylase 6B 0.00 −0.18 −0.29 −0.15 0.07 −0.05 0.83 0.91 1.80 2.22 1.27 1.43
LMCD1 LIM and cysteine-rich domains 1 0.00 0.15 0.14 −0.35 −0.04 0.04 0.63 1.39 1.56 1.56 2.47 1.98
MECOM Ecotropic viral integration site 1 0.00 0.08 0.09 −0.35 −0.01 0.02 −1.27 −0.62 −1.08 −1.51 −0.80 −1.22
MYB v-myb Myeloblastosis viral
oncogene homolog
0.00 −0.15 0.09 −0.07 −0.07 −0.22 −1.29 −0.67 −3.44 −3.70 −2.07 −1.04
MYBL2 v-myb Myeloblastosis viral
oncogene homolog-like 2
0.00 0.09 0.07 −0.29 −0.06 −0.09 −1.07 −0.63 −6.49 −8.62 −4.42 −0.89
(Continued)
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Table 5 | Continued
Gene
symbol
Name Time (h)
0 1 2 4 6 8 18 24 72 ~168 ~500 >4500
MYC v-myc Myelocytomatosis viral
oncogene homolog
0.00 0.39 −0.22 −0.77 −0.22 −0.54 −1.06 −0.47 −1.78 −1.65 −0.71 0.95
NCOA5 Nuclear receptor coactivator 5 0.00 0.01 −0.03 −0.46 −0.13 −0.13 −1.32 −0.44 −1.24 −0.88 −0.11 −1.36
NFATC2 Nuclear factor of activated T-cells 1 0.00 0.54 −0.14 −0.27 −0.02 0.26 0.50 1.18 1.57 1.54 1.85 3.17
NFATC4 Nuclear factor of activated T-cells 4 0.00 −0.08 −0.28 −0.27 −0.06 −0.32 1.19 0.89 2.01 2.36 1.08 1.54
NME1 Non-metastatic cells 1, protein
NM23A
0.00 0.09 −0.04 −0.41 −0.07 −0.08 −1.08 −0.60 −2.51 −2.78 −1.13 −0.75
NR4A1 Nuclear receptor subfamily 4, group
A, member 1
0.00 −0.29 −0.23 −0.01 0.24 0.16 0.88 1.35 2.27 1.94 0.32 2.33
NRL Neural retina leucine zipper 0.00 0.45 0.29 −0.19 0.22 0.10 −1.36 −0.86 −1.33 −0.71 −0.78 −0.81
PKNOX2 PBX/knotted 1 homeobox 2 0.00 −0.24 −0.32 −0.81 −0.25 −0.29 1.29 0.84 2.05 1.68 −1.99 −3.37
PPARD Peroxisome proliferator-activated
receptor delta
0.00 0.04 −0.15 −0.43 −0.06 −0.18 0.92 1.12 2.90 2.77 1.70 1.76
PPARGC1A PPAR gamma, coactivator 1 alpha 0.00 −0.16 −0.02 −0.53 −0.07 −0.16 −1.46 −1.27 −0.56 0.09 −0.23 0.89
PRDM13 PR domain containing 13 0.00 0.12 0.03 −0.81 −0.20 −0.11 −1.61 −0.83 −2.42 −2.54 −1.42 −0.93
PSMC3 Proteasome 26S subunit, ATPase, 3 0.00 0.11 0.03 −0.33 −0.02 −0.01 −0.83 −0.45 −1.08 −1.26 −0.75 −0.44
PSMC3IP PSMC3 interacting protein 0.00 0.08 0.00 −0.40 0.05 −0.08 −1.12 −0.66 −4.29 −3.67 −1.48 −0.27
RORA RAR-related orphan receptor A 0.00 −0.32 −0.23 −0.24 −0.02 −0.15 −1.70 −1.38 −1.65 −2.14 1.25
RORC RAR-related orphan receptor C 0.00 0.58 0.47 −0.33 0.32 0.26 1.55 1.93 3.88 2.64 2.30 −0.67
RUNX3 Runt-related transcription factor 3 0.00 0.07 −0.02 −0.35 0.31 0.27 1.27 1.63 2.37 1.80 1.04 7.04
SAP30 Sin3A-associated protein, 30 kDa 0.00 0.14 0.04 −0.17 0.10 0.02 −1.02 −0.68 −1.76 −1.81 −0.81 −0.47
SIRT4 Sirtuin 0.00 0.01 −0.48 −0.20 0.17 0.12 1.18 1.00 3.10 2.87 2.01 2.45
SIVA1 SIVA1, apoptosis-inducing factor 0.00 0.02 −0.10 −0.54 −0.11 −0.11 −1.10 −0.56 −1.43 −2.25 −0.95 −1.51
SKIL SKI-like oncogene 0.00 −0.09 0.13 −0.48 −0.21 −0.02 1.16 1.04 2.10 2.52 1.23 1.47
SMAD7 SMAD family member 7 0.00 0.23 −0.05 −0.76 −0.14 0.04 0.80 1.03 2.04 2.13 1.38 0.93
SOX2 SRY -box 2 0.00 −0.02 −0.29 −0.36 −0.15 −0.44 −1.75 −1.37 −3.08 −2.71 −3.41 −2.02
SP6 Sp6 transcription factor 0.00 0.58 0.15 −0.04 0.18 −0.29 1.14 1.06 2.14 1.64 1.39 2.83
STAT5A Signal transducer and activator of
transcription 5A
0.00 −0.15 0.27 0.55 0.24 0.44 2.19 1.02 3.78 3.75 1.30 3.64
TADA2A Transcriptional adaptor 2 -like 0.00 −0.16 0.03 −0.41 −0.15 −0.10 −1.13 −0.56 −1.33 −1.53 −0.78 −0.52
TCF19 Transcription factor 19 0.00 0.00 −0.01 −0.30 −0.02 −0.02 −1.10 −0.44 −3.62 −4.45 −2.23 −0.99
TFAP4 Transcription factor AP-4 0.00 −0.08 −0.17 −0.35 −0.06 −0.11 −1.13 −0.67 −1.29 −1.74 −1.01 −0.57
TGFB1 Transforming growth factor, beta 1 0.00 0.61 0.94 1.10 1.92 2.00 2.80 2.90 3.69 4.82 3.25 4.63
TP53INP1 Tumor protein p53 inducible nuclear
protein 1
0.00 0.08 0.02 −0.14 −0.50 −0.34 1.14 1.14 3.98 4.39 2.37 1.94
TP73 Tumor protein p73 0.00 −0.01 −0.02 −0.31 −0.14 −0.27 0.95 1.33 2.57 2.15 1.98 1.84
UHRF1 Ubiquitin-like with PHD and ring
finger domains 1
0.00 0.06 0.06 −0.32 −0.08 −0.13 −1.20 −0.55 −3.44 −3.82 −1.60 −1.25
VGLL3 Vestigial like 3 0.00 0.05 0.19 −0.31 −0.11 0.03 1.32 1.46 2.53 2.47 2.15 1.74
VSX1 Visual system homeobox 1 0.00 0.15 −0.18 0.02 0.16 −0.20 −1.64 −1.98 −1.58 −1.16 0.51 −1.26
YY2 YY2 transcription factor 0.00 0.04 0.04 −0.24 −0.03 −0.02 −1.12 −0.73 −1.86 −0.72 −0.14 −1.70
ZCCHC12 Zinc finger, CCHC domain containing
12
0.00 −0.12 −0.20 −0.32 −0.27 −0.06 −1.25 −1.00 −2.01 −1.12 −1.03 −2.38
ZFP112 Zinc finger protein 112 homolog 0.00 −0.22 −0.31 −0.21 0.03 −0.17 −1.30 −0.70 −1.70 −1.98 −0.63 0.15
ZFP90 Zinc finger protein 90 homolog 0.00 −0.09 −0.08 −0.24 −0.04 −0.02 −1.40 −0.94 −1.43 −2.11 −1.02 −1.66
ZNF180 Zinc finger protein 180 0.00 −0.05 0.03 −0.26 −0.04 −0.08 −1.01 −0.69 −1.92 −1.60 −0.89 −0.81
ZNF26 Zinc finger protein 26 0.00 0.03 0.07 −0.20 0.11 −0.08 −1.10 −0.53 −1.26 −1.02 −0.22 −0.35
ZNF296 Zinc finger protein 296 0.00 0.16 0.15 −0.59 0.28 0.08 −1.10 −0.39 −1.52 −1.43 −0.48 −1.06
(Continued)
www.frontiersin.org December 2014 | Volume 4 | Article 344 | 17
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Haley et al. Epigenetic and transcription networks in NSCLC EMT
Table 5 | Continued
Gene
symbol
Name Time (h)
0 1 2 4 6 8 18 24 72 ~168 ~500 >4500
ZNF367 Zinc finger protein 367 0.00 0.32 0.02 −0.57 −0.30 −0.33 −1.39 −0.76 −4.92 −5.78 −3.30 −1.19
ZNF37A zinc finger protein 37A 0.00 −0.09 −0.18 −0.21 0.01 −0.10 −1.05 −0.55 −1.00 −0.83 −0.42 −0.52
ZNF551 Zinc finger protein 551 0.00 0.22 −0.01 −0.47 −0.16 −0.13 −1.07 −0.64 −1.66 −1.55 −0.67 −0.75
ZNF620 Zinc finger protein 620 0.00 −0.13 −0.24 −0.24 −0.10 −0.28 −1.14 −0.96 −2.06 −1.26 −0.78 −0.96
ZNF718 zinc finger protein 718 0.00 −0.11 −0.04 −0.24 −0.03 −0.14 −1.05 −0.69 −1.85 −1.42 −0.86 −1.31
ZNF729 Zinc finger protein 729 0.00 −0.11 0.05 −0.10 0.07 0.04 −1.12 −0.74 −3.69 −3.57 −2.22 −0.59
ZNF775 Zinc finger protein 775 0.00 0.08 0.18 −0.24 0.41 −0.10 0.61 1.01 1.33 1.40 1.11 0.41
ZNF782 Zinc finger protein 782 0.00 −0.14 −0.23 −0.40 −0.14 −0.28 −1.44 −0.86 −2.15 −1.60 −0.48 −1.36
Genes were selected based on expression in 6–8 h or 18–24 h time bins. TGFβ1, the doxycycline-induced transgene, served as an internal control. Log2 ratio values
are colored where red denotes increased in the mesenchymal state and green denotes decreased in the mesenchymal state.
CDMBX1, CITED4, RORC, VGLL3, RUNX3, and BHLHE40
were markedly increased. The homeodomain transcription fac-
tor DMBX1 has been shown to be required for reprograming of
induced pluripotent stem cells, and for midbrain development
(91). Several transcription regulators showed biphasic expres-
sion, where an early decrease in RNA abundance was followed
by an increase at the >6 months steady-state time point for
the helix-loop-helix dominant negative E-box binding inhibitor
ID2 and RAR-related orphan receptor RORA, while the reverse
was true for PBX/knotted 1 homeobox 2 (PKNOX2), which was
increased at early time points and markedly attenuated by 21 days
(Table 5).
Genes from the 6–8 and 18–24 h sets (16,058 genes each) were
used for GSEA correlations using oncogene and curated signature
datasets. The top ranked gene signatures, divided into functional
families and correlating with early and middle time points are
shown in Table 6. The LEF1 and NFκB activation signatures and
BMI1 and EZH2 inhibition signatures were correlated with the
mesenchymal state at early time points. Interestingly, HOXA9 tar-
get gene inhibition also was correlated with the mesenchymal state,
where crosstalk between HOXA9 and BMI1 can impact cell cycling
and senescence programs (92). The positive correlation of the mes-
enchymal state with HIF1 hypoxia signaling, embryonic stem cell
programs, and STAT signaling were observed at the early time
points. A mesenchymal correlation with Myc target inhibition
also was an early event (Table 6). Multiple cell cycle signatures
correlated the mesenchymal state with cell cycle inhibition at early
time points, consistent with previous complete EMT endpoint data
(Tables 1 and 2).
DISCUSSION
A detailed investigation of molecular differences contrasting iso-
genic epithelial and stem-like mesenchymal tumor cell states has
been undertaken in isogenic lung adenocarcinoma cell models
harboring mutant-KRas. Our observations reinforce the impor-
tant role that cancer stemness and EMT can have in driving drug
resistance in tumor cells (7, 8, 12, 17, 93) and highlight the wide
diversity of mechanisms (94) that can be used by tumor cells to
evade targeted- and chemo-therapies. Agents and combinations
successfully targeting mutant-KRas containing tumor cells, in an
epithelial or mesenchymal cell context, would have a marked
impact in the treatment of NSCLC and particularly pancreas can-
cer where trans-differentiation is a frequent event (22). An under-
standing of these mechanisms and molecular contexts will have
important implications in driving combinatorial drug therapy in
cancer patients in the future.
Mutation of the KRas oncoprotein leads to the interaction and
activation of BRaf/CRaf and Mek1/2 kinases and phosphoryla-
tion of Erk1/2 on the activation segment. Erk1/2 phosphorylation
on the loop TXY motif activated Erk1/2 catalytic activity and
leads to downstream cytoplasmic and nuclear pro-survival sub-
strate target phosphorylation. In both A549 and H358 models, a
markedly increased Erk active site phosphorylation was observed
in the mesenchymal state (Table S3 in Supplementary Material).
Similar to the H358 and A549 models described here we have
observed TGFβ mediated induction of EMT in mt-EGFR NSCLC
adenocarcinoma lines HCC4006 and HCC827 (data not shown).
A common feature in both mt-KRas and mt-EGFR models is an
elevated activation of the Erk1/2 kinases. These data support a
hypothesis that chronic Erk activation may contribute to the initi-
ation of EMT, and once EMT has occurred, Erk is further activated
in part through integrin/paxillin/FAK and TGFbetaR1 signaling
networks. Thus we suggest that KRas, through Erk, may act as
both to prime initiation of EMT and to maintain the mesenchymal
state once a transition has occurred. Preliminary RNA interfer-
ence studies indicate enhanced mesenchymal cell sensitivity to
Erk1/2 knockdown. Interestingly, synthetic lethality in multiple
mt-KRas backgrounds has been observed with knockdown of
Snail2/Slug (95).
Though our principle interest is in identifying key survival tar-
gets required for the viability of cells in the mesenchymal state, we
considered that druggable transcriptional or epigenetic regulators
acting early in the EMT process might serve as useful candidates.
Previous studies have highlighted the heterogeneity of distinct
EMT programs and the plethora of potential targets, for example,
FGFR (57), Axl (96), PDGFR (97), JAK-STAT (98, 99), FAK (100),
contributing to the viability of mesenchymal-like tumor cells in
a model specific manner. Given the complex nature of epigenetic
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Table 6 | Gene-set enrichment (GSEA) for RNA showing a close to or greater than twofold change between mesenchymal and epithelial cell
states, by 6–8 h or by 18–24 h time bins.
Phenotype Time bin (h) GSEA dataset Size NES NOM p-value FDR q-value
TRANSCRIPTION
Mes 18–24 LEF1_UP.V1_UP 131 −2.13 0.000 0.000
Mes 6–8 LEF1_UP.V1_UP 131 −1.14 ns ns
Mes 18–24 HINATA_NFKB_TARGETS_KERATINOCYTE_UP 73 −2.57 0.000 0.000
Mes 18–24 BMI1_DN.V1_UP 121 −2.25 0.000 0.000
Mes 6–8 BMI1_DN.V1_UP 121 −2.25 0.000 0.000
Mes 18–24 BMI1_DN_MEL18_DN.V1_UP 121 −2.84 0.000 0.000
Mes 6–8 BMI1_DN_MEL18_DN.V1_UP 121 −2.84 0.000 0.000
Mes 18–24 PRC2_EZH2_UP.V1_DN 146 −2.11 0.000 0.000
Mes 6–8 PRC2_EZH2_UP.V1_DN 146 −2.11 0.000 0.000
Epi 18–24 PRC2_EZH2_UP.V1_UP 145 1.74 0.000 0.003
Epi 6–8 PRC2_EZH2_UP.V1_UP 145 1.74 0.000 0.003
Epi 18–24 HOXA9_DN.V1_DN 168 1.57 0.001 0.023
Epi 6–8 HOXA9_DN.V1_DN 168 1.57 0.001 0.023
Mes 18–24 HOXA9_DN.V1_UP 163 −1.80 0.000 0.001
Mes 6–8 HOXA9_DN.V1_UP 163 −1.80 0.000 0.001
Epi 18–24 ELVIDGE_HYPOXIA_DN 142 2.31 0.000 0.000
Mes 18–24 ELVIDGE_HYPOXIA_UP 158 −2.26 0.000 0.000
Epi 18–24 MANALO_HYPOXIA_DN 285 3.24 0.000 0.000
Mes 18–24 MANALO_HYPOXIA_UP 172 −2.78 0.000 0.000
Mes 18–24 ESC_J1_UP_EARLY.V1_UP 137 −1.92 0.000 0.000
Mes 6–8 ESC_J1_UP_EARLY.V1_UP 137 −1.92 0.000 0.000
Mes 18–24 ESC_J1_UP_LATE.V1_UP 135 −2.16 0.000 0.000
Mes 6–8 ESC_J1_UP_LATE.V1_UP 135 −2.16 0.000 0.000
Epi 18–24 GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN 154 2.79 0.000 0.000
Mes 18–24 GARCIA_TARGETS_OF_FLI1_AND_DAX1_UP 52 −2.22 0.000 0.000
Epi 18–24 GARY_CD5_TARGETS_DN 418 2.62 0.000 0.000
Mes 18–24 GARY_CD5_TARGETS_UP 441 −2.22 0.000 0.000
Epi 18–24 MISSIAGLIA_REGULATED_BY_METHYLATION_DN 119 2.66 0.000 0.000
Mes 18–24 MISSIAGLIA_REGULATED_BY_METHYLATION_UP 112 −2.88 0.000 0.000
Mes 18–24 WIERENGA_STAT5A_TARGETS_GROUP1 106 −2.29 0.000 0.000
Mes 18–24 WIERENGA_STAT5A_TARGETS_GROUP2 45 −2.34 0.000 0.000
Mes 18–24 WIERENGA_STAT5A_TARGETS_UP 170 −2.43 0.000 0.000
Mes 18–24 DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN 482 −2.79 0.000 0.000
Epi 18–24 DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP 305 3.29 0.000 0.000
Mes 18–24 MYC_UP.V1_DN 134 −2.33 0.000 0.000
Mes 6–8 MYC_UP.V1_DN 134 −2.33 0.000 0.000
Epi 18–24 MYC_UP.V1_UP 158 2.45 0.000 0.000
Epi 6–8 MYC_UP.V1_UP 158 2.45 0.000 0.000
CELL CYCLE
Mes 18–24 RB_DN.V1_DN 114 −2.01 0.000 0.000
Mes 6–8 RB_DN.V1_DN 114 −2.01 0.000 0.000
Epi 18–24 RB_DN.V1_UP 125 1.54 0.008 0.027
Epi 6–8 RB_DN.V1_UP 125 1.54 0.008 0.027
Epi 18–24 RB_P107_DN.V1_UP 119 2.22 0.000 0.000
Epi 6–8 RB_P107_DN.V1_UP 119 2.22 0.000 0.000
Mes 18–24 E2F1_UP.V1_DN 164 −2.17 0.000 0.000
Mes 6–8 E2F1_UP.V1_DN 164 −2.17 0.000 0.000
Epi 18–24 E2F1_UP.V1_UP 171 1.87 0.000 0.001
Epi 6–8 E2F1_UP.V1_UP 171 1.87 0.000 0.001
Mes 18–24 CHANG_CORE_SERUM_RESPONSE_DN 194 −3.22 0.000 0.000
(Continued)
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Table 6 | Continued
Phenotype Time bin (h) GSEA dataset Size NES NOM p-value FDR q-value
Epi 18–24 CHANG_CORE_SERUM_RESPONSE_UP 208 2.26 0.000 0.000
Mes 18–24 CSR_LATE_UP.V1_DN 136 −2.84 0.000 0.000
Mes 6–8 CSR_LATE_UP.V1_DN 136 −2.84 0.000 0.000
Epi 18–24 CSR_LATE_UP.V1_UP 149 2.36 0.000 0.000
Epi 6–8 CSR_LATE_UP.V1_UP 149 2.36 0.000 0.000
Epi 18–24 MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN 56 2.60 0.000 0.000
Mes 18–24 MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_UP 56 −2.23 0.000 0.000
Signatures enriching from transcriptional regulation (top panel) and cell cycle regulation (bottom panel) are shown. Individual GSEA signatures are defined in detail at
http:// www.broadinstitute.org/ gsea/ msigdb/ index.jsp.
changes occurring as cells transition from epithelial to mesenchy-
mal states, we specifically defined networks, which can modulate
epigenetic states. The rationale is that pharmacological modu-
lation of epigenetic regulators can alter the expression of many
potential mesenchymal drug targets, potentially overcoming the
redundancy and heterogeneity of mesenchymal therapeutic tar-
gets. Here, we have identified multiple epigenetic regulatory net-
works, for example, the PRC1 complex, HP1γ, and BAF/Swi-Snf
complex, which can contribute to the formation and maintenance
of epithelial and mesenchymal tumor cell states. Overlapping tran-
scriptional programs also were observed, for example, the redun-
dant loss of epithelial state transcription (GRHL2, TRAPC2, EHF,
and OSR2) and splicing (ESRP1 and ESRP2) factors. This theme
of modulation of overlapping or redundant network components
was also observed for enhancers of the mesenchymal cell state (e.g.,
overlapping Zeb1/2, Snail1/2, Twist) and chromatin reprograming
machinery. Synthetic lethality and therapeutic reprograming of
the mt-KRas NSCLC models can be investigated by future RNAi
or CRISPR approaches and/or cDNA overexpression studies, using
the transcriptional and epigenetic nodes defined.
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Table S1 | Excel format table of RSEM normalized H358 and A549 genes
from RNA-Seq, edited where any read is non-zero.
Table S2 | Excel file of H358 and A549 phosphopeptides identified at 95%
confidence from ProteinPilot v4.0, where individual peptide spectra were
acquired four or more times.
Table S3 | Excel file of concordant phosphopeptide changes in the H358
and A549 models (where N ≥4).
Table S4 | Concordant protein changes between A549 and H358 models. All
proteins were identified at >95% confidence with two or more unique
peptides to conform to recommendations of Bradshaw et al. (38). Protein
isoform abundance was measured by LC-MS/MS of SILAC labeled peptides and
ratios between mesenchymal and epithelial cell states log2 linear scaled. Log2
ratio values in italics reflect p<0.05. The number of unique peptides identified
at 95% confidence, not shared with related proteins, are shown.
Table S5 | Expected benchmark GSEA and pathway prediction signatures
(IPA) for stemness,TGFβ signaling, and mutant-KRas signaling in H358 and
A549 KRas NSCLC models comparing isogenic epithelial and mesenchymal
cell states. These correlations serve as expected benchmarks for (A) stemness
(Mani, Thomson ref), active TGFβ signaling (EMT inducer in both models) and (B)
KRas signaling (KRas oncogene in both models). KRas signatures were
enhanced in the mesenchymal cell state relative to the isogenic epithelial state,
consistent with enhanced phospho-Erk in mesenchymal A549 and H358 cell
states (23, 57). Individual GSEA signatures are defined in detail at
http://www.broadinstitute.org/gsea/msigdb/index.jsp.
Table S6 | Reference RNA expression of transcriptional inducers of EMT
(top panel) and potential markers of stemness (bottom panel).
Table S7 | GSEA and pathway prediction analysis (IPA) shows statistically
significant enrichment of BMI1 target genes altered with EMT state.
Manual analysis of BMI1 target RNA expression indicating divergence in the
direction of signaling between H358 and A549 and divergence within each
model, suggesting while BMI1 target genes are enriched and differentially
expressed with changing EMT state, the direction is not uniform and other
factor(s) likely contribute along with BMI1.
Figure S1 | Immunoblot staining for fibronectin, E-cadherin, vimentin, the
doxycycline-inducedTGFβ1 transgene, and actin (control) in the
H358-dox-TGFβ model in epithelial (−dox) or mesenchymal (+dox) states
(5 days on doxycycline).
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